Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inno8 in Healthy Male Participants
NCT06649630Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Inno 8 in hemophilia A (14 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at Day 46. Started Sep 2024; status: completed.
02
Drugs
Inno 8
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06649630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649630.